
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Acurx Pharmaceuticals in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst M. Keller now forecasts that the company will earn ($2.03) per share for the year, down from their prior forecast of ($2.00). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2026 earnings at ($0.46) EPS and FY2027 earnings at ($1.66) EPS.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11).
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.
Check Out Our Latest Stock Report on Acurx Pharmaceuticals
Acurx Pharmaceuticals Stock Performance
NASDAQ ACXP opened at $0.94 on Monday. The stock’s fifty day moving average is $1.21 and its two-hundred day moving average is $1.89. The firm has a market capitalization of $5.20 million, a P/E ratio of -0.48 and a beta of -2.08. Acurx Pharmaceuticals has a fifty-two week low of $0.90 and a fifty-two week high of $7.54.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing antibiotics to treat bacterial infections, particularly those caused by Gram-positive bacteria. The company’s research centers on DNA polymerase IIIC inhibitors, a class designed to interfere with bacterial DNA replication. Its lead investigational candidate, ibezapolstat, is being developed to treat infections caused by Clostridioides difficile (C. difficile). Acurx has also pursued other antibiotic candidates for Gram-positive bacterial infections.
Featured Articles
- Five stocks we like better than Acurx Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
